It is well known that RBCs present in a major ABO mismatch bone marrow transplant (BMT) can cause clinical hemolysis. To prevent this infusion complication, the volume of RBCs in the bone marrow (BM) graft can be reduced via various RBC depletion techniques. This management of major ABO mismatch BMT varies considerably due to the lack of strong evidence-based guidelines. 1 In particular, it is not known what volume of residual incompatible RBCs is safe, especially for smaller pediatric patients. Patrick et al. 2 attempted to address this important question in the recent article Major ABO incompatible BMT in children: determining what residual volume of donor red cells can safely be infused following red cell depletion. Through a retrospective chart review of 78 children who underwent major ABO mismatch BMT (most after RBC depletion with pentaspan sedimentation), they identified only two patients who had clinically significant adverse events related to the infusion of ABO-incompatible BM. These two patients, who both developed significant renal impairment, received 3.66 and 3.9 ml of incompatible RBCs per patient kg (compared with the median volume of 1.6 ml/kg). The authors implied that clinically significant adverse events following major ABO-incompatible BMT only occur when patients receive 43 ml/kg of incompatible RBCs. This idea is inaccurate as we have observed clinically significant adverse events related to the infusion of major ABO-incompatible BM in patients who received o 3 ml/kg of incompatible RBCs. Here we report the details of this observation in one pediatric and one adult patient (Table 1) .
Patient 1 was a 45 kg 13-year-old female with treatment-related AML. Pre-BMT glomerular filtration rate was abnormal at 82 ml/min/1.73 m 2 body surface area, but her serum creatinine was normal at 0.5 mg/dL. She received busulfan and fludarabine as a reduced intensity conditioning regimen. The patient was O+, while the 8/8 HLA-matched unrelated donor was A+. After RBC depletion with hydroxyethyl starch sedimentation, the RBC volume in the BMT product was reduced from 458 to 51 ml (1.1 ml/kg). Hydration with 2x maintenance IV fluids was started 4 h before infusion and acetaminophen, diphenhydramine and hydrocortisone were administered as infusion premedications. The BM graft was infused over 4.4 h (0.26 ml/kg/h RBCs) and the patient received a dose of IV furosemide following the infusion. No significant adverse event occurred during the infusion. Post infusion the patient began to have hemoglobinuria. At 6 h postinfusion serum creatinine increased to 1.6 mg/dL with an elevated potassium of 5.4 mmol/L and bilirubin of 2.2 mg/dL. Given the patient's evolving renal impairment which included decreased urine output, she was given IV furosemide and started on a renal dose dopamine infusion. At 9 h post-infusion, creatinine peaked at 1.7 mg/dL (340% above baseline). Cyclosporine, valacylovir, voriconazole and day +1 methothrexate were held. Mycophenolate mofetil was started as an alternative GvHD prophylaxis agent. Hyperhydration was continued as the patient continued to have hemoglobinuria. On day +4, hemoglobinuria resolved and creatinine stabilized at 0.9 m/dL. Previously held nephrotoxic medications were resumed, but methotrexate was given at 50% dosing on day +3 and day +6. She engrafted and was discharged from the hospital on day +27.
Patient 2 was a 92 kg 30-year-old female with hemoglobin SS disease. Pre-BMT glomerular filtration rate (111 ml/min/1.73 m 2 body surface area) and serum creatinine (0.8 mg/dL) were both normal. She received busulfan, fludarabine and rabbit antithymocyte globulin as a reduced intensity conditioning regimen. The patient was O+, while the 8/8 HLA-matched unrelated donor was B+. The patient's anti-B IgM titer was 1:64 and IgG was 1:256. Red cell depletion was attempted twice using the COBE cell processor (TerumoBCT, Lakewood, CO, USA), but the BM product still contained 90 ml of RBCs (0.98 ml/kg). Hydration with 200 ml/h normal saline was started 6 h before the infusion, and diphenhydramine and hydrocortisone premedication were given. Initially 50 ml of the BM product was infused over 1.1 h. The patient was noted to have an increase in blood pressure (142/90) during this infusion, but otherwise tolerated the initial infusion well. After a 2.2 h rest, the remaining 100 ml of the BM product was then infused over 1.3 h, during which she became more hypertensive (177/120). Post infusion the patient began to have hemoglobinuria. At 4 h post-infusion creatinine had increased to 1.6 mg/dL with an elevated bilirubin of 9.7 mg/dL (increased from 3.8 mg/dL). Tacrolimus was dose reduced, planned administrations of methotrexate were canceled, and alternative GvHD prophylaxis with mycophenolate mofetil was started. At 19 h post infusion, creatinine increased further to 2.4 mg/dL. On day +4, creatinine peaked at 2.8 mg/dL (350% above baseline) and subsequently gradually normalized. She engrafted and was discharged from the hospital on day +31.
The two reported patients both had evidence of clinically significant hemolysis-induced renal impairment despite only receiving~1 ml/kg of incompatible RBCs in the infused BM product. Premedication, hyperhydration and relatively slow infusion rates failed to prevent this complication. These patients demonstrate that the suggested threshold of 3 ml/kg of incompatible RBCs proposed by Patrick et al. is not always safe. Rather, the reported patients support the notable finding by these authors that hemolytic events were not significantly associated with the volume of incompatible RBCs in the infused BM graft. Nonetheless, a larger volume of incompatible RBCs is likely to cause more problems. A retrospective study of ABO-incompatible RBC transfusions due to error found that patients who received 450 ml of incompatible RBCs were more likely to experience clinical adverse events than patients transfused o 50 mL. 3 It is not clear if the risk of developing clinical hemolysis is more associated with the absolute volume of incompatible RBCs infused or the RBC volume per recipient weight. It is also likely that variables other than the volume of incompatible RBCs (possibly pre-BMT renal function, isoagglutinin titers and conditioning regimen) have an important role in determining which patients have significant hemolysis after major ABO mismatch BMT. Further research is needed in this area, but it is likely that the 'safe' threshold volume of incompatible RBCs will vary from patient to patient depending on these variables.
Given that the determinants of clinical hemolysis after major ABO mismatch BMT remain unclear, our institutions have adopted different strategies to manage this issue. For pediatric patients Letter to the Editor
